Positive: Purple Biotech reports positive results in Phase 2 CM24 pancreatic cancer study with potential new therapy.

From GlobeNewswire: 2024-08-16 08:12:00

Purple Biotech presented positive interim data from a Phase 2 CM24 pancreatic cancer study at ASCO 2024, showing improvements in overall survival, progression free survival, and objective response rate. Plans to expand the clinical program to additional indications are based on the novel oncology target CEACAM1. Cash runway extended to Q3 2025.

The Phase 2 study evaluated CM24 in combination with nivolumab and chemotherapy in pancreatic cancer patients. Interim results showed a 26% reduction in the risk of death, a 28% reduction in progression risk, and a 26% overall response rate in the experimental arm compared to standard-of-care. Additional biomarker data supports the potential of CM24 in other indications.

Purple Biotech’s NT219 therapy was found to significantly suppress cancer stem cells, offering a potential new mechanism to combat resistance to KRAS inhibitors. Findings presented at AACR 2024 show promising results in solid tumors, suggesting a novel therapy for solid tumors and potential biomarkers for treatment. Financially, the company reported decreased expenses and operating losses for the three months ended June 30, 2024.



Read more at GlobeNewswire:: Purple Biotech Reports Second Quarter 2024 Financial